Kornimate/medical-research-clean huggingface dataset:
effects of a scapular-focused exercise protocol

Conditions: Rotator Cuff Syndrome of Shoulder and Allied Disorders

Summary: background: current clinical practice still lacks consistent evidence in the physiotherapy management of rotator cuff related pain syndrome (rcs). the purpose of this trial was to compare the effectiveness of a scapular-focused treatment with and without real-time electromyographic biofeedback (emgbf) to a control therapy in patients with rcs. methods: 60 patients with rcs were divided into three groups: scapular-focused exercise protocol group (p_g n=20), scapular-focused exercise protocol with emgbf group (p+emgbf_g n=20) and control therapy group (ct_g n=20). values of pain and function \[shoulder pain and disability index (spadi) questionnaire, complemented by the numeric pain rating scale (nprs) and disabilities of the arm, shoulder and hand (dash) questionnaire\], scapular stabilizer neuromuscular control (ssnc), scapular stabilizer activation onset (ssao), dynamic scapular alignment, range of motion (rom) and glenohumeral flexor and abductor muscle strength (gms) were assessed at baseline and after 6-weeks and compared within and between groups.

in order to advance the understanding of the value of scapular-focused exercise for rotator cuff related syndrome, a new trial was designed with the main objective of comparing pain and function outcomes between three different treatment protocols for patients with rcs: p_g - scapular-focused exercise protocol without electromyographic biofeedback (emgbf) p+emgbf_g - scapular-focused exercise protocol supported by real-time emgbf ct_g - control therapy group with manual therapy (glenohumeral joint physiologic and accessory mobilization) , massage to reduce upper trapezius (ut) stiffness, and shoulder rotation strengthening into external rotation every outcomes was assessed at the beginning of treatment, and then, weekly until completed 6 weeks of treatment.

Eligibility criteria:
inclusion criteria: 1- age between 18 and 60 years; 2 - primary complaint of shoulder pain 3 - rcs clinical diagnosis exclusion criteria: 1. - neurological symptoms; 2. - positive thoracic outlet syndrome (screened with allen's and adson's tests); 3. - history of shoulder surgery or fracture; 4. - structural injuries confirmed by imaging (e.g. ligaments and labrum); 5. - symptoms reproduced by cervical examination; 6. - unable to commit to scheduled treatments; 7. - anti-inflammatory drug use

Keywords: scapula neuromuscular activity and control rotator cuff related pain syndrome scapular dyskinesis electromyographic biofeedback control therapy pain and function
pilot study testing a new strategy for management of spontaneous preterm birth

Conditions: Preterm Labor

Summary: preterm birth is a major public health problem, and actual treatments are not very efficient. the purpose of this study is to test the efficiency of a combined use of montelukast and nifedipine to treat preterm labor. investigators aim to reduce uterine contractions more efficiently than with the use of nifedipine only.

an inflammatory process is involved in 60% of preterm births. moreover, investigators previously demonstrated that enzymes of lipoxygenase pathway are present in uterine smooth muscle, and that an additive tocolytic effect can be obtained from the combined use of montelukast and nifedipine. methods: this is a double-blinded randomized controlled assay performed at the chus on two groups of 50 women. women will be selected when admitted for preterm labor with a gestational age between 26 and 34 weeks. the first group will receive nifedipine for 48 hours, as described by the standard protocol at the chus, in addition to 10 mg of montelukast per day, until delivery or 35 weeks of pregnancy. the second group will receive nifedipine for 48 hours, as described by the standard protocol at the chus, in addition to a placebo per day, until delivery or 35 weeks of pregnancy. cervical secretions and urine will be sample at the admission, after one week and every two weeks during treatment.

Eligibility criteria:
inclusion criteria: * women with 24-34 weeks of pregnancy * indication for tocolysis exclusion criteria: * preterm labor before 26 or after 34 weeks of pregnancy * minor patients * patients with other obstetrical pathology * twin pregnancies * fetal distress * severe congenital fetal malformation * anti-phospholipid syndrome * lupus * gestational diabetes * nephropathy * congenital heart disease * obvious causes of infection associated with prematurity * patients with viral infections (hiv, hepatitis) * patients already treated with montelukast

Keywords: preterm labor montelukast uterine contractions
in vitro drug sensitivity testing of fresh human samples

Conditions: Myeloproliferative Disorders; Lymphoproliferative Disorders

Summary: hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (aml) or chronic myeloid leukemia (cml)) and lymphoproliferative disorders (as chronic lymphoid leukemia (cll), non-hodgkin lymphoma (nhl) and multiple myeloma (mm)) . over the last decade, the treatments have evolved significantly but the overall survival remains limited, especially for the aml and mm patients. there's an ongoing imperative to continue in-vitro and in-vivo studies to better evaluate the anti-cancer drugs sensitivity and therefore improving the response to treatments and open new fields of application. the healthy control group will be contributing to produce some pertinent and significant data for the results of the index cases group. the investigators aim to analyze 10 differents drugs, common use in chemotherapy or immunotherapy and evaluate by 2 ways the sensitivity: first, flow cytometry (cells apoptosis by annexine v and propidium iodide) on fresh samples and in a second time, monitoring of the blasts in the mouse's blood after injection.


Eligibility criteria:
inclusion criteria: * index cases: patients with myeloproliferative or lymphoproliferative disorders. * controls: patients without hematological disease, without chemotherapy ((≤ 5 years.) and without immunosuppressive treatment at the study time. * age ≥ 18 y.o for all the patients exclusion criteria: * age \< 18 y.o * pregnant or breastfeeding woman * patients deprived of their liberty by judicial or administrative decision.

Keywords: hematological malignancies lymphoid myeloid multiple myeloma anticancer drugs sensitivity new treatments
zikalliance children cohort (zikalliancech)

Conditions: Zika Virus

Summary: the aim of this proposal is to evaluate the causal relationship between zika virus (zikv) infections in pregnancy and congenital malformations. the study will estimate the absolute and relative risks of congenital malformations and other adverse outcomes of pregnancy among women who become infected with zikv during pregnancy compared to uninfected pregnant women, also leading to further validation of the congenital zika syndrome.

the aim of this proposal is to evaluate the causal relationship between zika virus (zikv) infections in pregnancy and congenital malformations. the study will estimate the absolute and relative risks of congenital malformations and other adverse outcomes of pregnancy among women who become infected with zikv during pregnancy compared to uninfected pregnant women, also leading to further validation of the congenital zika syndrome. the study will also determine the zikv maternal to child transmission rate and evaluate co-factors or effect modifiers that account for the large variability seen in the preliminary absolute risk estimates derived from population figures and reporting of microcephaly in different states in brazil and across latin america. the study will carry out a pregnant women (pw) multicentre cohort study in areas across latin america and the caribbean. women will be enrolled early in pregnancy and followed every 4 weeks, in connection with their routine antenatal care visits. at each visit, urine and blood samples will be collected, tested and stored. among pw reporting recent or current undifferentiated fever/rash syndrome at any point in time, the acute illness episode will be characterized in greater detail. pw with suspected zikv infection (i.e. meeting the pan american health organization (paho) clinical case definition) during pregnancy will be managed according to national protocols. irrespective of symptoms, pregnant women will be followed prospectively and revisited at birth (or after abortion) for a detailed documentation of the outcome of their pregnancy. live newborns will receive a detailed neonatal examination. in the course of examination of the newborns, biological samples will be collected and stored. other potential causes of congenital abnormalities (torchs infections in the mother, toxic substances, chromosomal abnormalities), and potential effect modifiers (for example past flavivirus infections/vaccinations, socio-economic status) will also be assessed. with appropriate counselling and consent, biological samples of newborns with severe abnormalities, deceased newborns, stillborn babies, and aborted foetuses from zikv-infected mothers will be collected to help elucidate the aetiological contribution of zikv in neurological and other congenital malformations. children of women infected with zikv during pregnancy - and a subset of the children born to uninfected women - will be followed prospectively after birth for the assessment of neuro-developmental milestones.

Eligibility criteria:
inclusion criteria: * born within the pregnant woman cohort * born to mothers with confirmed zika exclusion criteria: -
bronchoscopic thermal vapor ablation (btva) for lung volume reduction

Conditions: Emphysema; Chronic Obstructive Pulmonary Disease

Summary: to assess the safety and efficacy of btva for the treatment of patients with heterogeneous upper lobe emphysema.

all subjects meeting the eligibility criteria and who provide written informed consent will be enrolled. immediately prior to btva treatment, an initial bronchoscopy will be performed to evaluate the baseline condition of the airways and to confirm anatomy of the lung segments targeted for btva treatment. up to 3 segments in either the right or left upper lobe will be treated with a vapor dose of 10 calories per gram of lung tissue (10 cal/g). targeted lobe for treatment will be based on lobar disease severity.

Eligibility criteria:
inclusion criteria: 1. age: \> 40 and ≤ 75 years old 2. diagnosis of heterogeneous emphysema with upper lobe predominance 3. fev1 \< 45% predicted 4. tlc \> 100% predicted 5. rv \> 150% predicted 6. 6-minute walk test \> 140 meters 7. mmrc ≥ 2 (mmrc) 8. non-smoking for 3 months 9. optimized medical management and completed pulmonary rehabilitation exclusion criteria: 1. known α-1-antitrypsin deficiency 2. bmi \ 35 kg / m2 3. history of pneumothorax within previous 18 months 4. history of heart and / or lung transplant, lung volume reduction surgery (lvrs), median sternotomy, bullectomy, and/or lobectomy 5. respiratory infections or recurring copd exacerbations \> 3 hospitalizations in past 12 months or active infection 6. history of the (ef) ≤ 40%; stroke; unstable myocardial ischemia; fev1 \< 15% predicted; dlco \< 20% predicted; of pulmonary hypertension; indwelling pacemaker or implantable cardiac defibrillator (icd); pregnancy or breastfeeding

Keywords: emphysema copd lung volume reduction btva
retrospective descriptive study of platelet transfusion in patients with palliative hematologic malignancies at the university hospital of besançon

Conditions: Platelet Transfusion; Palliative Care

Summary: development of palliative care is less effective for patients with hematologic malignancies. limited data is available for end of life care in this population, moreover with thrombocytopenic patients. thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. as it represent a scarce, limited resource, the ethical principles are in conflict in this setting. the purpose of this study was to describe retrospectively platelet transfusion in the six last few month of life of patients with hematologic malignancies at the chu of besançon (france) between 01/07/15 and 31/12/16.


Eligibility criteria:
inclusion criteria: * patient with hematological malignancies * transfused in platelet at least once in the last 6 months of life * hospitalised or follow up at the chu of besancon at least once * dead during the period of the study exclusion criteria: * patient with other oncologic malignancies * not transfused in platelet in the last 6 months of life * never hospitalised or follow up at the chu of besancon * alive

Keywords: platelet transfusion palliative care
sedation regimen in patients undergoing cardiac electrophysiology study and ablation : a comparison between dexmedetomidine-remifentanil and midazolam-remifentanil combinations

Conditions: Cardiac Arrhythmia

Summary: cardiac ablation is an invasive procedure requiring anesthetic support for immobility and analgesia. benzodiazepines and opioids are the most commonly used agents, while they are associated with respiratory depression and hypotension. the aim of this study was to compare the effect of remifentanil and dexmedetomidine, which exerts sedative and analgesic effect without serious respiratory depression, with conventional midazolam/remifentanil combination on sedative and analgesic levels in patients undergoing endocardial ablation.


Eligibility criteria:
inclusion criteria: * patients scheduled for elective cardiac ablation for atrial fibrillation exclusion criteria: * asa physical status class ≥ 3, * respiratory disease, * end stage renal disease, * illiterate

Keywords: cardiac ablation
the effect of time-restricted eating on liver metabolism

Conditions: NAFLD; Obesity; Nutritional and Metabolic Diseases

Summary: numerous studies have established the role of nutrition on obesity and its related metabolic diseases, which together affect a billion individuals worldwide. evidence indicate that meal timing regulates numerous metabolic processes suggesting that meal time manipulation may be a simple intervention against obesity and its metabolic diseases. time-restricted eating (tre) is a dietary manipulation that involves restricting food intake to 6-10 h/day with no energy intake the rest of the day. in rodents, tre significantly decreases hepatic steatosis and dyslipidemia, while it supports a healthier hepatic cellular content even without caloric restriction, potentially by alternating activation of nutrient sensing mechanisms and effects on circadian oscillations. however, an understanding of the effect of tre on liver health in people is not clear. accordingly, we will conduct a randomized controlled trial in people with overweight/obesity and hepatic steatosis to determine the effect of 9 h tre for 12 weeks, on key metabolic outcomes in liver health: 1) intrahepatic triglyceride content using magnetic resonance imaging; 2) de novo lipogenesis during fasting and postprandial conditions using administration of deuterated water in conjunction with mathematical modeling. the proposed study will enable us to determine the effect of meal timing on metabolic function in people with nafld.


Eligibility criteria:
inclusion criteria: * age 25-75 years * men and women * body mass index 25-45 kg/m2 * clinical diagnosis of nafld * self-reported habitual eating period more than or equal to 14 h per day. exclusion criteria: * shift worker, recent or expected travel crossing time zones * fasting \>12-h/day more than once a week \*\> once a week no food intake after 18:00 * habitually waking up before 04:00 and sleeping before 22:30 * unstable weight (\>5% change in the last 2 months) * diabetes mellitus or alcoholic liver disease * sleep disorder * history of or current eating disorder * cancer in last 5 years * conditions that render subject unable to complete all testing procedures * use of medications that affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued * smoking or illegal drug use * pregnant or breastfeeding * having metals in the body * cognitive impairment * gastrointestinal or bariatric surgery that affects nutrient digestion and absorption unable to grant voluntary informed consent or comply with the study instructions individuals who are not yet adults (infants, children, teenagers) * individuals that are unable to lie motionless on the mri scanner for an hour or \*have tattoos or tattooed eyeliner * alcohol abuse * prisoners
h-side branch stent, a new stent for the treatment of true bifurcation lesions

Conditions: Coronary Artery Disease

Summary: intervention for coronary bifurcation lesion is about 10\~20% of entire percutaneous coronary intervention (pci). bifurcation lesion is difficult to be treated and prognosis of pci at bifurcation lesion has been poorer compared to that at non-bifurcation lesion. furthermore, occlusion of side branch frequently occurred during pci. several techniques to prevent occlusion of side branch have been developed, but outcomes are not to be satisfied. h-side branch stent is developed to treat coronary side branch lesion and composed of proximal, connecting and distal parts. in vivo study performed in pigs showed effective h-side branch stent. this study is to confirm safety and efficacy of h-side branch stent for treatment of coronary side branch lesion.


Eligibility criteria:
inclusion criteria: * older than 20 years old * patient with angina or asymptomatic ischemic cardiomyopathy who is required to be treated with stent at coronary bifurcation lesion * bifurcation lesion with 2.5\~4.0mm of main vessel diameter, \<30mm of main vessel length and ≥2.0mm of branched vessel diameter exclusion criteria: * acute myocardial infarction * confirmed or suspicious presence of thrombus in target lesion * in-stent restenosis lesion * visual angulation with ≥75° * lesion with severe calcification or severe tortuosity * left main lesion * chronic total occlusion lesion * graft lesion * contraindication to antiplatelet drugs * left ventricular dysfunction (lvef ≤40%) * severe hepatic dysfunction (≥2.5 times than reference of ast or alt) * renal dysfunction (serum creatinine \> 2.0mg/dl) * history of cerebral hemorrhage, pulmonary or gastrointestinal bleeding * hypersensitivity of aspirin, clopidogrel or contrast media * pregnant woman or possibility of pregnancy during clinical study period

Keywords: side branch stent coronary bifurcation lesion
risk stratification and benefits with cardiac resynchronization therapy (crt)

Conditions: Heart Failure; Ventricular Arrhythmias

Summary: this is an observational study to learn which patients benefit from crt therapy and to track the clinical changes that help identify the risk-level of crt patients.

the purpose of the study is two-fold. first, to determine if an algorithm can be developed based on pre-implant clinical variables to predict response to crt-d therapy. second, the study aims to determine in patients implanted with crt-d if the combined use of ctnt and bnp can further predict and risk-stratify hf improvement and all-cause mortality. additionally, novel biochemical markers defining cardiac mortality in high risk patients detected by plasma proteomic analysis in the crt-d patients will be evaluated. this study represents a combination of previous crt studies that evaluated these variables independently. data from this study will be pooled with data from previous studies to build a more complete picture of crt therapy.

Eligibility criteria:
inclusion criteria: * meets current clinical indications for crt-d therapy * patient is 18 years old or older * ability to independently comprehend and complete all qol questionnaires * patient has the ability to perform the 6-minute hall walk test (6-mhw) with the only limiting factor being fatigue or shortness-of-breath * ability to provide informed consent for a study and be willing and able to comply with the prescribed follow-up exclusion criteria: * inability to successfully implant an intravascular lead and crt-d device. (i.e. exclude epicardial leads) within 30 days of initial procedure. * myocardial infarction in the last 3 weeks * unstable angina in the last 3 weeks * status 1 classification for cardiac transplantation * currently participating in a clinical trial that includes an active treatment arm * life expectancy of less than 12 months. * recent (within 1 week) administration of nesiritide™ or inotropes * patients in whom revascularization is expected * patient is pregnant
assessment of duration of action, safety & toleration of uk369,003 and cialis in patients with erectile dysfunction

Conditions: Impotence

Summary: assessment of duration of action, safety \& toleration of different formulations and doses of uk-369,003 and cialis in patients with male erectile dysfunction. patients should have previously been on pde5 inhibitors and have been respondents to the drug. duration of treatment is 4 weeks.


Eligibility criteria:
inclusion criteria: * erectile dysfunction exclusion criteria: * alpha blockers and nitrates of any preparation
incidence of acute pulmonary embolism in covid-19 patients on ct angiography and relationship to d-dimer levels

Conditions: Covid-19 With Positive RT-PCR

Summary: reports of acute pulmonary embolism (ape) associated with covid-19 have emerged in the literature. for example, chen et al. described 25 pulmonary ct angiograms examinations from 1008 covid-19 patients; 10 were positive for pulmonary embolism mostly as segmental or sub-segmental ape. case reports of ape in covid-19 patients have been published. cui et al. found an incidence of deep venous thrombosis in intensive care unit (icu) patients with severe covid-19 pneumonia near to 25% (20/81), however without any correlation with potential ape. despite these initial reports, it is not clear whether ape is more frequent in covid-19 patients or if the association is just random. in favor of the former, d-dimer levels have been reported as elevated in patients with covid-19 by two studies, and it has been suggested an independent association between the severity of the disease and the level of d-dimer. finally, tang et al. showed that anticoagulant therapy is associated with a decreased mortality at day-28 in severe covid-19 patients, in favor of a possible associated coagulopathy. the purpose of this study is to describe the rate of pulmonary embolus in patients classified as covid-19 infection and who underwent chest ct angiography. the purpose of this study is to describe the rate of pulmonary embolus in patients classified as covid-19 infection and who underwent chest ct angiography.


Eligibility criteria:
inclusion criteria: * positive sars-cov-2 rt-pcr * chest ct angiography available * patient is aged 18yo or above exclusion criteria: * expressed opposition to participate * adults under guardianship

Keywords: covid-19 pulmonary embolism ct angiography